【原美源伯根】Cencora (COR) 2023年年度报告「NYSE」.pdf

《【原美源伯根】Cencora (COR) 2023年年度报告「NYSE」.pdf》由会员分享，可在线阅读，更多相关《【原美源伯根】Cencora (COR) 2023年年度报告「NYSE」.pdf（20页珍藏版）》请在三个皮匠报告上搜索。

1、Summary Annual Report2023203 About Cencora05 CEO letter12 Financial highlights14 Management team15 Board of Directors16 GAAP/Non-GAAP financial measures18 Corporate informationTable of contents3AboutCencoraCencora is a leading global pharmaceutical solutions organization centered on improving the li

2、ves of people and animals around the world.We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies.Care providers depend on us for the secure,reliable delivery of pharmaceuticals,healthcare products,and solutions.34CEO letter45To our sha

3、reholders:Fiscal 2023 was a seminal year for Cencora as we united under our new,globally inclusive identity and took key steps to advance our position at the center of healthcare.Our evolution to Cencora unites our team members under a name that better reflects our impact on healthcare as we continu

4、e to build on our commercial strengths.Guided by our purpose,powered by our foundation in pharmaceutical distribution,and differentiated by the breadth of solutions we provide our partners,we continue to execute on our strategic imperatives to advance our core business and enhance our capabilities t

5、o drive value for all our stakeholders.Strong performance and execution on pharmaceutical-centric strategy Our consolidated revenue was$262 billion,up 10%,adjusted operating income increased by 4%to$3.3 billion,and our full year adjusted diluted EPS was$11.99,an increase of 9%.Solid underlying busin

6、ess fundamentals,broad-based utilization trends,and a continued focus on efficiency allowed us to deliver strong results in the year.U.S.Healthcare Solutions segment operating income grew 6%,powered by our teams strong execution as we capitalized on our pharmaceutical-centric strategy.We continue to